MA-WASABI/ZERO-CIRCLE
10.7.2024 15:01:34 CEST | Business Wire | Press release
Zero Circle, a sustainable finance marketplace, and Wasabi Technologies, the hot cloud storage company, have partnered to develop a suite of sustainability-focused solutions for cloud storage that give businesses the data they need to make decisions that reduce their environmental impact.
Wasabi cloud storage integrated Zero Circle’s invoice-based carbon footprint calculator to give customers transparency and real-time assessment of their carbon footprint. Customers can upload their Wasabi invoice to Zero Circle’s carbon calculator to determine their estimated CO2 footprint based on actual data stored in a Wasabi storage region, increasing the accuracy of their ESG benchmarking with their peers and helping them make more sustainable business decisions.
According to the Wasabi 2024 Global Cloud Storage Index, sustainability ranks among the top three most important considerations for buyers when choosing a cloud storage service. Factors like ESG commitments, energy-efficient architecture design, and native tools for carbon footprint calculation are all increasingly important to modern enterprises as they adopt cloud infrastructure services. As a result, the survey found that cloud service providers must deliver accurate, reliable tools, metrics, and programs to meet customer expectations.
This joint initiative leverages Zero Circle's deep expertise in sustainability and product carbon footprint measurement with Wasabi's leadership in cloud storage to drive sustainability in the cloud storage industry and create innovative solutions that support businesses with their sustainability initiatives. The solution's unique features and flexibility make it a powerful resource for companies seeking to measure and track their cloud sustainability, such as real-time emissions calculations integrated directly into the purchases from supply chain partners.
“Partnering with Zero Circle underscores Wasabi’s dedication to providing top-tier, sustainable cloud storage solutions,” said David Boland, vice president of cloud strategy at Wasabi Technologies. “Zero Circle's carbon footprint calculation has already enabled Wasabi, our partners, and customers to gain a deeper understanding of our environmental impact. By integrating this solution into our supply chain, we are amplifying these benefits for everyone involved.”
"Announcing our collaboration with Wasabi marks a significant step in advancing environmental sustainability within the cloud storage sector,” said Hemanth Setty, founder and CEO of Zero Circle. “This partnership leverages our combined strengths and underscores our mutual dedication to fostering a more sustainable future, paving the way for innovative and groundbreaking solutions.”
The carbon footprint solution is now available to all Wasabi customers. The Zero Circle – Wasabi collaboration will also explore other eco-friendly initiatives, such as renewable energy procurement and carbon offset programs in an effort to further reduce environmental impact of cloud storage.
Additional Resources:
- For more information on Wasabi’s work with Zero Circle, visit wasabi.com/sustainability.
- To try Zero Circle’s invoiced-based carbon footprint calculator for Wasabi, visit https://cust.zerocircle.eco/wasabi.
- Join Wasabi, Zero Circle, and 451 Research July 16 at 1 p.m. ET/10 a.m. PT to learn how establishing sustainability goals for IT can help your business meet regulatory compliance more quickly. Read more details here.
About Zero Circle
Zero Circle is a green finance marketplace that simplifies access to green capital for mid-tier businesses. Its AI-powered platform streamlines sustainability assessments and reporting and automates financial and sustainability KPIs to incentivize green financing. The company helps its customers finance and build sustainable practices by tracking, managing, and reporting sustainability and financial performance with lenders, partners, and customers.
Click here to learn more about Zero Circle or follow them on LinkedIn and Twitter.
About Wasabi Technologies
Recognized as one of the technology industry’s fastest growing companies, Wasabi is on a mission to store the world's data by making cloud storage affordable, predictable and secure. With Wasabi, visionary companies gain the freedom to use their data whenever they like without being hit with unpredictable fees or vendor lock-in. Instead, they’re free to build best-of-breed solutions with the industry’s fastest-growing ecosystem of independent cloud application partners. Customers and partners all over the world trust Wasabi to help them put their data to work so they can unlock their full potential. Visit wasabi.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240710254246/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom